INDIA'S Indian Oil Corporation (IOC), the nation's biggest oil firm, has tied up imports from the US and taken additional volumes from Saudi Arabia to make up for the bulk of the volumes lost because of sanctions prohibiting buying oil from Iran, top officials said today (17).
Iran supplied more than a tenth of India's oil needs before the reimposition of the US sanctions against the Persian Gulf nation stopped supplies this month.
"We have tied up supplies from alternate sources. No single country can make up for the volumes lost, that's why we are keeping our sourcing diversified. We are fairly diversified in our sourcing and we have robust sourcing in place to make up for all of the Iranian oil," IOC Chairman Sanjiv Singh told reporters in New Delhi.
India bought close to 24 million tonnes of crude oil from Iran in the fiscal ended March 31. Of this, IOC sourced about 9 million tonnes from Iran.
IOC and other Indian refiners stopped importing crude oil from Iran this month following the US' move to end sanction waivers.
To make up for the shortfall, IOC has used optional volumes available from suppliers such as Saudi Arabia. Also, it has for the first time signed term import contracts with two US suppliers, he said, adding in all 4.6 million tonnes of crude oil from the US has been signed up for 2019.
IOC director A K Sharma said the company has an annual contract to buy 5.6 million tonnes of crude oil from Saudi Arabia. On top of this, it has the option to import an additional two million tonnes.
"We have exercised our optional volumes with Saudi Arabia and will be importing two million barrels of additional crude oil from Saudi Arabia in six months period beginning July," he said, adding the optional volumes imported from July to December total to about 1.5-1.6 million tonnes.
From the US, IOC has signed a deal with Norwegian oil company Equinor for buying three million tonnes of crude during the year and an additional 1.6 million tonnes from Algerian national oil company Sonatrach.
Equinor and Sonatrach produce crude oil in the US.
Singh said refiners import crude oil from a wide range of sources and have been lining up alternate supplies for the past months.
"The US was to take a decision on waiver extension in April and Indian refineries had prepared plans for all eventualities. We have alternate sources lined up to make up for any shortfall," he said.
The US president Donald Trump last year withdrew from the 2015 nuclear deal between Iran and world powers and revived a range of sanctions against the Persian Gulf nation. It, however, granted a six-month waiver from sanctions to eight countries China, India, Japan, South Korea, Taiwan, Turkey, Italy, and Greece but with a condition that they would reduce their purchases of Iranian oil.
The waiver began in November 2018 and expired on May 2.
India had agreed to restrict its monthly purchase to 1.25 million tonnes to get the waiver. But since it had made robust purchases in the period prior to November 2018, India's overall crude oil imports from Iran totalled nearly 24 million tonnes in 2018-19 as compared to 22.6 million tonnes bought in the 2017-18.
"We have optional volumes (over and above the term contracts) from a number of suppliers which we can exercise to make up for any shortfall from Iran," Singh said. "We can also go to the spot (or current) market to source crude."
IOC has the option to take 0.7 million tonnes of crude oil from Mexico on top of its committed purchase of 0.7 million tonnes during the year. Similarly, it has optional volumes of 1.5 million tonnes from Kuwait and another 1 million tonnes from the UAE, Sharma said.
"We have all the supplies tied up and I think globally crude will be readily available but it is difficult to say what the impact will be on price," Singh added.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.